|
Quality Committee Learning Lab SeriesMaryann Oertel of UNC discussed how a tiered inventory system and the Drug Supply Chain Resource Guide can be used to strengthen planning and response during supply disruptions. STAQ Pharma provided practical guidance on how to read FDA Form 483 observations and what they may signal about supplier quality and supply risk.
|
Supply Readiness White PaperPersistent and unpredictable drug shortages continue to strain healthcare systems and compromise patient care. To better understand the root causes and identify practical solutions, EDSA launched a multi-stakeholder initiative analyzing real-world case studies across critical medications.
Our new white paper, “From Shortages to Strategy: Using Case Studies to Identify Pathways to Prevent Future Disruptions in Essential Medicines,” highlights key findings from EDSA’s Supply Readiness Committee. By applying structured analysis to essential medicines, the report uncovers patterns of market dynamics, behavioral drivers, regulatory challenges, and opportunities for reform. |
Drug Supply Chain Resource GuideCreated by the EDSA Quality Committee with input from many EDSA members, this guide is designed to increase awareness and utilization of resources that could help health systems and other supply chain stakeholders to factor supply chain reliability and quality into their contracting and purchasing decisions.
This guide can help leaders address manufacturing quality issues by aligning their purchasing practices with measurable standards of quality and reliability, ultimately driving towards a more resilient pharmaceutical supply chain. |
Prescription Drug Tariff Webinar
Webinar on prescription drug tariffs and their impact on pricing, supply chains, and patient access. Our expert speaker, Marta Wosinska broke down key trends, policy changes, and what they mean for manufacturers, providers, and consumers.
|
